secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001193125-24-146510
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA advisory panel strongly recommends approval of Guardant's Shield blood test for CRC screening
--------------------------------------------------------------------------------

- FDA advisory panel voted 8-1 that Shield is safe, 6-3 that it is effective, and 7-2 that benefits outweigh risks.
- Shield blood test showed 83% sensitivity for colorectal cancer detection and 90% specificity for advanced neoplasia in ECLIPSE study.
- FDA decision on premarket approval expected later in 2024; Shield is on track to become first FDA-approved blood test for CRC screening.
- Approximately 50 million eligible Americans are not up-to-date with CRC screening; Shield offers a blood-draw alternative to stool-based tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524146510/0001193125-24-146510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524146510/d843201d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-146510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer